{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:28:21Z","timestamp":1773844101405,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,18]]},"DOI":"10.7759\/cureus.80756","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:07:42Z","timestamp":1742292462000},"source":"Crossref","is-referenced-by-count":1,"title":["Triple-Negative Breast Cancer: A Retrospective Study of 23 Cases in Morocco"],"prefix":"10.7759","author":[{"given":"Leila","family":"Abdallaoui Maane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil","family":"Ismaili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abderrahim","family":"Siati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Fareh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adil","family":"Elghanmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"Bouziyane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Dehayni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1684\/bdc.2013.1740","article-title":"Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives (Article in French)","volume":"100","author":"Gon\u00e7alves A","year":"2013","unstructured":"Gon\u00e7alves A, Sabatier R, Charafe-Jauffret E, et al.. Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives (Article in French). Bull Cancer. 2013, 100:453-64. 10.1684\/bdc.2013.1740","journal-title":"Bull Cancer"},{"key":"ref2","article-title":"Cancer Registry of the Greater Casablanca Region, Year 2004","author":"Benider A","year":"2007","unstructured":"Benider A, Bennani Othmani M, Harif M, et al.. Cancer Registry of the Greater Casablanca Region, Year 2004. Morocco; 2007."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal A","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011, 61:69-90. 10.3322\/caac.20107","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0915","article-title":"Tackling the diversity of triple-negative breast cancer","volume":"19","author":"Turner NC","year":"2013","unstructured":"Turner NC, Reis-Filho JS. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res. 2013, 19:6380-8. 10.1158\/1078-0432.CCR-13-0915","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart MJ","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005, 353:1659-72. 10.1056\/NEJMoa052306","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-016-0346-y","article-title":"Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features","volume":"16","author":"Derkaoui T","year":"2016","unstructured":"Derkaoui T, Bakkach J, Mansouri M, et al.. Triple negative breast cancer in North of Morocco: clinicopathologic and prognostic features. BMC Womens Health. 2016, 16:68. 10.1186\/s12905-016-0346-y","journal-title":"BMC Womens Health"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6874-12-35","article-title":"Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology","volume":"12","author":"Rais G","year":"2012","unstructured":"Rais G, Raissouni S, Aitelhaj M, et al.. Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology. BMC Womens Health. 2012, 12:35. 10.1186\/1472-6874-12-35","journal-title":"BMC Womens Health"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-0086-2","article-title":"Pattern of metastatic spread in triple-negative breast cancer","volume":"115","author":"Dent R","year":"2009","unstructured":"Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009, 115:423-8. 10.1007\/s10549-008-0086-2","journal-title":"Breast Cancer Res Treat"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12558-013-0252-2","article-title":"Clinical and prognostic aspects of triple-negative breast cancers at the breast unit of CHU Le-Dantec in Dakar (Article in French)","volume":"5","author":"Gueye M","year":"2013","unstructured":"Gueye M, Mbaye M, Niasse F, et al.. Clinical and prognostic aspects of triple-negative breast cancers at the breast unit of CHU Le-Dantec in Dakar (Article in French). Afr J Cancer. 2013, 5:42-7. 10.1007\/s12558-013-0252-2","journal-title":"Afr J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-1669-4","article-title":"The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy","volume":"18","author":"Zaky SS","year":"2011","unstructured":"Zaky SS, Lund M, May KA, et al.. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy. Ann Surg Oncol. 2011, 18:2858-65. 10.1245\/s10434-011-1669-4","journal-title":"Ann Surg Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1208","article-title":"Triple-negative breast cancer: risk factors to potential targets","volume":"14","author":"Schneider BP","year":"2008","unstructured":"Schneider BP, Winer EP, Foulkes WD, et al.. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008, 14:8010-8. 10.1158\/1078-0432.CCR-08-1208","journal-title":"Clin Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-08-1005","article-title":"Risk factors for triple-negative breast cancer in women under the age of 45 years","volume":"18","author":"Dolle JM","year":"2009","unstructured":"Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev. 2009, 18:1157-66. 10.1158\/1055-9965.EPI-08-1005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke C","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, et al.. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008, 26:1275-81. 10.1200\/JCO.2007.14.4147","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.1009","article-title":"TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer","volume":"26","author":"Carey LA","year":"2008","unstructured":"Carey LA, Rugo HS, Marcom PK, et al.. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol. 2008, 26:1009. 10.1200\/jco.2008.26.15_suppl.1009","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0165","article-title":"A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer","volume":"15","author":"Wang D","year":"2019","unstructured":"Wang D, Feng J, Xu B. A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer. Future Oncol. 2019, 15:2779-90. 10.2217\/fon-2019-0165","journal-title":"Future Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid P","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, et al.. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018, 379:2108-21. 10.1056\/NEJMoa1809615","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson M","year":"2017","unstructured":"Robson M, Im SA, Senkus E, et al.. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017, 377:523-33. 10.1056\/NEJMoa1706450","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton JK","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, et al.. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018, 379:753-63. 10.1056\/NEJMoa1802905","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia A","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al.. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021, 384:1529-41. 10.1056\/NEJMoa2028485","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/340730-triple-negative-breast-cancer-a-retrospective-study-of-23-cases-in-morocco","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:07:45Z","timestamp":1742292465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/340730-triple-negative-breast-cancer-a-retrospective-study-of-23-cases-in-morocco"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.80756","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}